UK 24-Year Study: Early Diabetes Control Saves Lives

A Study from the UK Reveals That Early Blood Sugar Control May Offer Near-Lifelong Protection

A study from the UK, conducted by researchers at the University of Oxford's Diabetes Trials Unit, has delivered one of the most compelling findings in diabetes research history: aggressively controlling blood sugar right after a Type 2 diabetes diagnosis can reduce your risk of heart attack and early death for up to 24 years — and possibly for life. Published in The Lancet in 2024, this research extends the already-celebrated UK Prospective Diabetes Study (UKPDS), making it the longest-running randomized controlled trial in diabetes care ever conducted.

What the Researchers Did

Beginning in 1977, researchers enrolled 5,102 people newly diagnosed with Type 2 diabetes across the UK. Participants were divided into two groups: one received intensive glycemic control using sulfonylureas, insulin, or metformin, while the other followed conventional control through diet alone. After 20 years of the active trial and a 10-year post-trial monitoring period, scientists then linked 1,489 surviving participants to UK National Health Service (NHS) records for an additional 14 years — bringing total follow-up to as long as 42 years per participant.

The Key Findings

The results were striking. Compared to conventional (diet-only) control, intensive treatment with sulfonylureas or insulin produced:

• 17% reduction in heart attack risk (absolute risk reduction: 3.3%)
• 10% reduction in risk of death from any cause (absolute risk reduction: 2.7%)
• 26% reduction in microvascular complications — including kidney disease and eye damage (absolute risk reduction: 3.5%)

Metformin therapy showed even stronger results for overweight participants:

• 31% reduction in heart attack risk (absolute risk reduction: 6.2%)
• 20% reduction in risk of death from any cause (absolute risk reduction: 4.9%)

Critically, these benefits showed no signs of waning even 24 years after the original trial ended — a phenomenon researchers call the "legacy effect."

Understanding the Numbers in US Terms

In the UK, blood sugar targets are often expressed in mmol/L. For US patients accustomed to mg/dL: the intensive control group aimed for fasting glucose near 108 mg/dL (6.0 mmol/L) and an HbA1c below 7.0% — consistent with what the American Diabetes Association (ADA) currently recommends as a standard target for most non-pregnant adults with Type 2 diabetes. This alignment makes the UK findings directly applicable to American patients following ADA guidelines.

Why This Matters for US Patients

In the United States, approximately 38 million people live with diabetes, and many are diagnosed without immediately starting medication — often beginning with lifestyle changes alone. This UK research powerfully suggests that waiting too long to achieve good blood sugar control could cost decades of protection against heart attacks and premature death.

The study reinforces that the window right after diagnosis is not just important — it may be the most important. Whether your doctor recommends metformin, a sulfonylurea, or another agent, this research supports acting early and decisively. If you've recently been diagnosed, ask your healthcare provider about your individualized HbA1c target and what medications may be right for you.

This international perspective is especially valuable for US patients because the UKPDS followed real-world patients over an extraordinarily long timeframe that no US trial has yet matched, lending its conclusions exceptional credibility.

Citation

Adler, Coleman, Leal et al. "Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)." The Lancet, 2024. PMID: 38772405. DOI: 10.1016/S0140-6736(24)00537-3